NCT06781437 Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)
| NCT ID | NCT06781437 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Lymphoproliferative Syndrome, Autoimmune |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,500 participants |
| Start Date | 2022-02-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,500 participants in total. It began in 2022-02-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 18 years of enrollment * Diagnosis of lymphoma or lymphoproliferative syndrome between January 1980 and September 2021 * Signature of the informed consent form where applicable Exclusion Criteria: * none
Contact & Investigator
Pier Luigi Zinzani, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06781437 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoproliferative Syndrome, Autoimmune. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06781437 currently recruiting?
Yes, NCT06781437 is actively recruiting participants. Contact the research team at pierluigi.zinzani@unibo.it for enrollment information.
Where is the NCT06781437 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06781437 clinical trial?
NCT06781437 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Pier Luigi Zinzani, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 5,500 participants.